Plus   Neg

Stock Alert: Sonoma Pharmaceuticals More Than Doubles

Shares of Sonoma Pharmaceuticals, Inc. (SNOA) are surging over 100% on Friday morning. The pharma company has teamed up with Crown Laboratories to launch Microcyn technology-based anti-itch over-the-counter products.

SNOA is currently trading at $12.54, up $6.34 or 102.22%, on the Nasdaq.

Sonoma and Crown announce they have entered into a license and supply agreement for the exclusive rights to sell and market products for the OTC dermatological market in the US.

Crown plans to sell Sonoma's Microcyn technology dermal sprays and gels targeting itch and pain under Sarna brand.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Intel Corp. (INTC) Thursday reported a profit and revenues for the first quarter that trumped Wall Street estimates, driven by continued demand for PCs. Moving ahead, the company lifted its full-year outlook. Santa Clara, California-based Intel reported first-quarter profit of $3.36 billion or $0.82... A third of those American adults now refusing to get vaccinated would get vaccinated if they could take a pill instead of getting the vaccine shot, according to a poll conducted by Quadrant Strategies and commissioned by biotechnology company Vaxart, Inc. A pill vaccine is expected to overcome vaccine resistance of millions of Americans. While reporting financial results for the first quarter on Thursday, Biogen Inc. (BIIB) raised its adjusted earnings guidance for the full-year 2021, but maintained revenue outlook. For fiscal 2021, the company raised its adjusted earnings guidance to a range of $17.50 to $19.00 per share from the...
Follow RTT